Rafferty Asset Management LLC Sells 48,278 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Rafferty Asset Management LLC decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 22.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 165,816 shares of the company's stock after selling 48,278 shares during the period. Rafferty Asset Management LLC owned about 0.19% of CRISPR Therapeutics worth $6,527,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Western Pacific Wealth Management LP lifted its position in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Spire Wealth Management raised its holdings in CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after acquiring an additional 1,482 shares in the last quarter. MCF Advisors LLC acquired a new position in CRISPR Therapeutics during the fourth quarter valued at approximately $80,000. First Horizon Advisors Inc. grew its stake in CRISPR Therapeutics by 33.4% in the fourth quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company's stock valued at $80,000 after purchasing an additional 511 shares in the last quarter. Finally, AdvisorNet Financial Inc grew its stake in CRISPR Therapeutics by 91.1% in the fourth quarter. AdvisorNet Financial Inc now owns 2,478 shares of the company's stock valued at $98,000 after purchasing an additional 1,181 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This represents a 12.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John Greene purchased 7,000 shares of the company's stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the transaction, the director now directly owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 14,021 shares of company stock worth $594,771. Company insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Barclays dropped their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. Truist Financial boosted their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Wednesday. Needham & Company LLC restated a "buy" rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday. Finally, HC Wainwright restated a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Stock Down 5.8%

CRISPR Therapeutics stock traded down $2.26 during trading hours on Wednesday, hitting $36.99. The stock had a trading volume of 1,997,884 shares, compared to its average volume of 1,686,710. The business's 50 day simple moving average is $37.34 and its 200-day simple moving average is $42.22. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $67.88. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of -8.46 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter last year, the company earned ($1.43) EPS. The company's revenue for the quarter was up 71.6% compared to the same quarter last year. Research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.